Eyepoint Pharmaceuticals said Phase 3 LUGANO results support DURAVYU’s potential in wet age-related macular degeneration, sharpening focus on a possible new treatment option. Attention now shifts to the upcoming LUCIA trial and the company’s retinal pipeline.
published
Eyepoint Pharmaceuticals said Phase 3 LUGANO results support DURAVYU’s potential in wet age-related macular degeneration, sharpening focus on a possible new treatment option. Attention now shifts to the upcoming LUCIA trial and the company’s retinal pipeline.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.